Back to top
more

Keros Therapeutics (KROS)

(Delayed Data from NSDQ)

$11.12 USD

11.12
111,221

-0.56 (-4.79%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $11.11 -0.01 (-0.09%) 6:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (157 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics

by Zacks Equity Research

AES and four peers screen as low price-to-book buys, highlighting undervalued stocks with solid growth profiles as 2025 draws to a close.

Kinjel Shah headshot

5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close

by Kinjel Shah

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

Zacks Equity Research

KROS or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Keros Therapeutics (KROS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Kinjel Shah headshot

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

by Kinjel Shah

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Zacks Equity Research

Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros

by Zacks Equity Research

StoneCo, General Motors, Enersys, Deutsche, Keros have been highlighted in this Screen of The Week article.

Kinjel Shah headshot

Buy These 5 Best Value Stocks to Boost Your Portfolio in December

by Kinjel Shah

Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.

Zacks Equity Research

What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?